Section 5 of 6

Economic information and modeling report

31 evidence topics · 16 sources

Modeling overview

Summary

No published cost-effectiveness analysis or budget impact model of tovorafenib in any pLGG population was identified, and no health technology assessment has evaluated tovorafenib for first-line use. All tovorafenib HTA activity concerns relapsed or refractory pLGG. The EU Joint Clinical Assessment found no direct comparative data; the only included comparison, an unanchored matching-adjusted indirect comparison with dabrafenib plus trametinib in BRAF V600E-mutated disease, had effective sample sizes of 5.81 to 14.26. In Germany, the company-reported annual therapy cost of tovorafenib was €239,561.93 to €479,123.86 per patient, with 6 to 156 patients in the statutory health insurance target population; IQWiG judged the lower cost bound plausible and the upper bound overstated because tablets cost less than the suspension, and a G-BA decision is scheduled for early November 2026. The French HAS granted early access on July 2, 2026 for patients with BRAF-altered pLGG who progressed after at least 1 systemic treatment and were previously treated with, or ineligible for, dabrafenib plus trametinib, and the NICE appraisal (ID6557) was in scoping with no expected publication date.

For the comparator class, NICE (TA977, May 2024) recommended dabrafenib plus trametinib for BRAF V600E-mutated LGG in children and young people aged 1 year and over who need systemic treatment, with a confidential discount, a 1.2 severity weighting on QALYs, an acceptable ICER of around £30,000 per QALY, and confidential LGG ICERs judged to be within the cost-effective range. A company-sponsored analysis for England and Wales reported a probabilistic ICER of £26,606 per QALY (70.7% probability of cost-effectiveness at £30,000 per QALY). An independent Canadian microsimulation of first-line dabrafenib plus trametinib versus chemotherapy (TADPOLE efficacy; 2024 Canadian dollars; 1.5% discount rate) estimated 2.21 incremental QALYs at an incremental cost of CAD 554,769, a base case ICER of CAD 251,027 per QALY with lifetime treatment, and CAD 44,740 per QALY with 2 years of treatment; the authors concluded that a price reduction would be required. A CDA-AMC reimbursement review of dabrafenib plus trametinib for pLGG with BRAF V600 mutations (PX0375) was identified, but its pharmacoeconomic content could not be retrieved.

For sales, Day One reported U.S. OJEMDA net product revenue of $57.2 million in 2024 (launch in May 2024) and $155.4 million in 2025, with 4,635 prescriptions in 2025 and 2026 guidance of $225 million to $250 million. Management projections disclosed for the Servier tender offer assumed OJEMDA development as a front-line therapy and projected total company net revenue (including other products, royalties, and milestones) of $261 million in 2026, rising to a peak of $1,131 million in 2035. Day One estimated approximately 1,100 new U.S. BRAF-altered pLGG diagnoses per year in patients younger than 25 years and an addressable relapsed, progressive, or refractory pool of 2,000 to 3,000 patients per year. FIREFLY-2 enrollment was expected to complete in the first half of 2026, with data in mid-2027 and potential approval in 2028. Servier completed its acquisition of Day One on April 23, 2026 (equity value approximately $2.5 billion); no OJEMDA revenue figures for 2026 quarters were located.

OJEMDA U.S. net product revenue and prescriptions, 2024 and 2025

“Product revenue, net increased $98.2 million, from $57.2 million for the year ended December 31, 2024 to $155.4 million for the year ended December 31, 2025 due to increased sales of OJEMDA in the United States.” (opens the source at this quote in a new tab)

“OJEMDA net product revenue of $52.8 million and $155.4 million for the fourth quarter and full year 2025, respectively” (opens the source at this quote in a new tab)
“Fourth quarter prescription volumes increased to 1,394 and total 2025 prescriptions were 4,635, representing 181% growth versus 2024 (April launch), and demonstrating strong and growing patient demand, increasing treatment persistence and expanding prescriber adoption” (opens the source at this quote in a new tab)
“Company reaffirmed its previously announced 2026 U.S. OJEMDA net product revenue guidance of $225 million to $250 million” (opens the source at this quote in a new tab)

Revenue guidance for 2026 and first-line FIREFLY-2 timeline

“2026 OJEMDA U.S. net product revenue is projected to be between $225 million and $250 million, representing 53% year-over-year growth at the midpoint” (opens the source at this quote in a new tab)
“Deliver on 2026 OJEMDA net product revenue guidance, with a focus on increasing persistency and driving new patient starts to support continued OJEMDA adoption as standard of care (SOC) in 2L pediatric low-grade glioma (pLGG)” (opens the source at this quote in a new tab)
“Complete enrollment in the pivotal Phase 3 FIREFLY-2 clinical trial in first-line pLGG in the first half of 2026, enabling a mid-2027 data readout and a potential approval in 2028” (opens the source at this quote in a new tab)

Company statements on the U.S. patient population and market opportunity, including front-line use

“Based on incidence results published in academic journals, we estimate that approximately 1,100 patients under the age of 25 are newly diagnosed with BRAF-altered pLGG every year. We partnered with an epidemiology firm to perform SEER and CBTRUS registry analysis that estimates the prevalence, as of January 1, 2017, in the United States for BRAF-altered patients with pLGG under the age of 25 to be 26,000. The estimated addressable pool of recurrent, progressive, or refractory patients with pLGG for tovorafenib is approximately between 2,000 to 3,000 per year at steady state.” (opens the source at this quote in a new tab)
“Premium reimbursement precedents for high impact therapeutics in rare diseases, oncology and pediatrics.” (opens the source at this quote in a new tab)
“Chronic duration of treatment required over many years to address these slow-growing and relentless tumors.” (opens the source at this quote in a new tab)
“We believe that treating patients before they have undergone multiple rounds of toxic chemotherapy has the potential to both improve the efficacy of tovorafenib and reduce the overall burden of therapy and related toxicities associated with the use of currently-employed cytotoxic agents.” (opens the source at this quote in a new tab)

Management long-range revenue projections disclosed in the Servier tender offer

“In preparing the Projections, Day One management assumed (1) that Day One pursues the development and commercialization within the United States of OJEMDA, including as a front-line therapy, with no additional equity financing, and receives additional revenue from sales of OJEMDA outside the United States from its partner” (opens the source at this quote in a new tab)
“Total Net Revenue, as presented herein, reflects net revenue associated with product sales, as well as potential future royalty and milestone payments.” (opens the source at this quote in a new tab)

Fiscal year	Total net revenue, dollars in millions
2026E	“261”
2027E	“349”
2028E	“419”
2029E	“645”
2030E	“738”
2031E	“832”
2032E	“961”
2033E	“998”
2034E	“1,062”
2035E	“1,131”
2036E	“800”

Acquisition of Day One by Servier

“Transaction represents total equity value of approximately $2.5 billion.” (opens the source at this quote in a new tab)
“The acquisition strengthens Servier’s leadership in low-grade glioma and expands the Group’s position in oncology with the addition of a marketed product and pipeline focused on rare cancers.” (opens the source at this quote in a new tab)
“Day One already markets the product in the United States and has licensed the rights outside the U.S. to Ipsen.” (opens the source at this quote in a new tab)

Germany: annual therapy costs and target population for tovorafenib in relapsed or refractory pLGG (IQWiG assessment of the company dossier)

“Der pU ermittelt für Tovorafenib Jahrestherapiekosten pro Patientin bzw. Patient in Höhe von 239 561,93 € bis 479 123,86 €. Sie bestehen ausschließlich aus Arzneimittelkosten für die Darreichungsform eines Pulvers zur Herstellung einer Suspension. Für die Untergrenze ist dies plausibel. Für die Obergrenze fallen unter Berücksichtigung der Darreichungsform Tabletten geringere Kosten an, als vom pU ausgewiesen.” (opens the source at this quote in a new tab)
“Ausgehend von einem GKV-Anteil in Höhe von 89,16% [11,12] berechnet der pU eine Spanne von 6 bis 156 Patientinnen und Patienten in der GKV-Zielpopulation.” (opens the source at this quote in a new tab)
“Insgesamt ist die vom pU angegebene Anzahl der Patientinnen und Patienten in der GKV-Zielpopulation aus den oben genannten Gründen in der Untergrenze unterschätzt und in der Obergrenze mit Unsicherheit behaftet.” (opens the source at this quote in a new tab)
“Der pU gibt keine Kosten für zusätzlich notwendige GKV-Leistungen an. Dies ist plausibel.” (opens the source at this quote in a new tab)

Germany: G-BA orphan drug benefit assessment procedure status

Field	Quoted record
Start of procedure	“15.05.2026”
Publication of benefit assessment	“17.08.2026”
Decision	“Anfang November 2026”
Remarks	“Arzneimittel zur Behandlung eines seltenen Leidens (Orphan Drug)”

EU Joint Clinical Assessment: absence of comparative evidence and indirect comparison uncertainty

“As FIREFLY-1 is a non-comparative study, no direct comparative data are available to inform any of the PICOs and no data are available to inform an analysis within a connected network of evidence.” (opens the source at this quote in a new tab)
“The HTD does not include comparative evidence addressing patients in the full claimed indication, corresponding to PICOs 1-4 in the assessment scope.” (opens the source at this quote in a new tab)
“The effective sample size (ESS) for the analyses of all outcomes is small (ranging from 5.81 to 14.26), leading to statistical imprecision (i.e., wide confidence intervals) for the resulting effect estimates.” (opens the source at this quote in a new tab)

France: HAS early access authorization

“Autorisation d’accès précoce octroyée” (opens the source at this quote in a new tab)
“en monothérapie pour le traitement des patients âgés de 6 mois et plus, atteints d’un gliome pédiatrique de bas grade (GBG) porteur d’une fusion ou d’un réarrangement de BRAF ou d’une mutation V600E et précédemment traités ou non éligibles à un traitement par l’association du dabrafénib et du tramétinib, et qui ont progressé après au moins un traitement systémique.” (opens the source at this quote in a new tab)

England: NICE appraisal of tovorafenib in development

“Suggested remit: To appraise the clinical and cost effectiveness tovorafenib within its marketing authori-sation treating people aged 6 months and over with relapsed or refractory paediatric low-grade glioma (LGG) with a BRAF fusion or rearrangement or BRAF V600 mutation.” (opens the source at this quote in a new tab)
“In progress. Scoping commencing” (opens the source at this quote in a new tab)

England: NICE appraisal of dabrafenib plus trametinib (TA977) recommendation, model, and cost-effectiveness judgment

“Dabrafenib with trametinib is recommended, within its marketing authorisation, as an option for treating: • low-grade glioma (LGG) with a BRAF V600E mutation in children and young people aged 1 year and over who need systemic treatment” (opens the source at this quote in a new tab)
“The list price for dabrafenib is £2,800 per 420‑pack of 10 mg dispersible tablets (company submission). The list price for trametinib is £376 per 4.7 mg bottle of 0.05 mg per ml powder for oral solution (company submission).” (opens the source at this quote in a new tab)
“The company developed an individual-based state transition model which included analyses for both LGG and HGG cohorts. There were 3 health states common to both analyses: progression-free after first treatment, progressed and death.” (opens the source at this quote in a new tab)
“The committee concluded that severity weights of 1.2 (LGG) and 1.7 (HGG) applied to the QALYs were appropriate for this evaluation.” (opens the source at this quote in a new tab)
“So, the committee concluded that an acceptable ICER would be around £30,000 per QALY.” (opens the source at this quote in a new tab)
“In the LGG analysis, because of confidential commercial arrangements for other treatments in the model, the exact cost-effectiveness estimates are confidential and cannot be reported here.” (opens the source at this quote in a new tab)
“The committee concluded that treatment duration should reflect the marketing authorisations and a stopping rule should not be included for either LGG or HGG.” (opens the source at this quote in a new tab)

Cost-effectiveness of dabrafenib plus trametinib in BRAF V600E pLGG: England and Wales model

“The economic evaluation uses an individual-based state-transition model, whereby simulated patients move through a series of progression health states. Efficacy data were taken from the TADPOLE trial, supplemented by external data.” (opens the source at this quote in a new tab)
“The analysis was conducted from the perspective of the National Health Services and Personal Social Services over a lifetime horizon and in line with the National Institute of Clinical Excellence reference case.” (opens the source at this quote in a new tab)
“The probabilistic incremental cost per quality-adjusted life-year (QALY) gained was £26 606 after QALY weighting, with an 70.7% probability of D+T being a cost-effective treatment option at a £30 000/QALY gained willingness-to-pay threshold.” (opens the source at this quote in a new tab)

Cost-effectiveness of first-line dabrafenib plus trametinib versus chemotherapy in BRAF V600E pLGG: Canadian microsimulation

“Cost-effectiveness was calculated from a Canadian public health care payer perspective at a discount rate of 1.5%, expressed in 2024 Canadian dollars. The base case modeled lifetime Dab-Tram treatment, to reflect clinical paradigms of indefinite Dab-Tram therapy.” (opens the source at this quote in a new tab)
“Dab-Tram was associated with a 2.21 quality-adjusted life-year (QALY) gain at an incremental cost of $554,769 Canadian dollars (CAD) compared with standard chemotherapy. The base case incremental cost-effectiveness ratio (ICER) was $251,027 CAD/QALY. Two-year Dab-Tram resulted in an ICER of $44,740 CAD/QALY, while ICERs across other scenarios ranged from $26,013 CAD to $410,196 CAD/QALY.” (opens the source at this quote in a new tab)
“In the context of clinical paradigms favoring indefinite treatment, Dab-Tram is unlikely to prove cost-effective at the present price and would require a price reduction to facilitate sustained access.” (opens the source at this quote in a new tab)

Cost-effectiveness analysis or budget impact model of tovorafenib

No evidence found.

Comparator, health states, and analytic conventions of the England and Wales model

“The structure of the decision-analytical model is depicted in Figure 1 and uses an individual-based state-transition model, composed of 4 primary mutually exclusive health states: (1) progression-free, (2) progressive disease (split onto 5 subhealth states), (3) transformation into HGG (split onto 2 subhealth states), and (4) death from any cause (glioma-related or nonglioma related).” (opens the source at this quote in a new tab)
“The comparator is established clinical management (ECM) consisting of chemotherapy C+V.” (opens the source at this quote in a new tab)
“The model simulates the patient event/life histories of a sufficiently large sample of pediatric patients with glioma (n = 2000) and uses what is commonly known as the Monte Carlo sampling approach.” (opens the source at this quote in a new tab)
“patients are followed over a lifetime horizon, an NHS/personal social services perspective is used, and costs and benefits are discounted at 3.5% per annum. Results are presented both deterministically and probabilistically. A total number of 1000 simulations are performed to obtain sufficient precision in the probabilistic analysis.” (opens the source at this quote in a new tab)

Treatment duration and stopping assumptions in the England and Wales model

“It is therefore assumed that treatment would be stopped when a patient reaches adulthood. As with current chemotherapies, D+T treatment is assumed to be stopped after a number of years (between 2 to 5 years) to balance unnecessary exposure to treatment and risk of toxicities with clinical need/benefit, reflecting the indolent nature of the condition, and the reducing hazard of progression with time and age.” (opens the source at this quote in a new tab)
“Because of the uncertainty, no treatment effect is assumed once patients stop treatment with the same of progression assumed between arms. Scenario analyses are conducted varying the maximum treatment duration (Appendix Table 1).” (opens the source at this quote in a new tab)
“The maximum treatment duration to minimize unnecessary exposure to treatment with respect to clinical need/benefit also remains an area of uncertainty and an option to retreat at progression is likely to reflect the preferred clinical strategy to avoid keeping patients on treatment unnecessarily but also save costs for the NHS.” (opens the source at this quote in a new tab)

Drug acquisition and administration cost assumptions in the England and Wales model

“Dabrafenib plus trametinib are available to the National Health Services (NHS) with a discount; although the size of the discount is confidential, the cost incurred by the NHS used in this economic evaluation.” (opens the source at this quote in a new tab)
“Drug administration costs for IV chemotherapy are taken from the NHS reference cost, with no administration costs assumed for oral treatments.” (opens the source at this quote in a new tab)

Utility values derived from adult studies in the England and Wales model

“For instance, the EQ-5D or SF-36 were not collected in the trial, and no appropriate decrement in utility were identified in a population such as that entering the economic evaluation. Consequently, utility decrements observed in adult population are used as a proxy to reflect the impact of glioma on quality of life irrespective of age. This is an important limitation because it remains unclear whether using adult decrements is a reasonable proxy for childhood gliomas.” (opens the source at this quote in a new tab)

Base-case incremental costs, quality-adjusted life-years, and severity weighting

“For the probabilistic analysis, the model estimates total discounted costs associated with D+T to be £155 470 compared with £86 645 for ECM, an incremental cost of £68 645. The total discounted QALYs for D+T are estimated to be 15.71 compared with 13.13 for patients treated with ECM, an incremental QALY gain of 2.58. The probabilistic (deterministic) ICER is £26 606 (£25 776) per QALY gained.” (opens the source at this quote in a new tab)
“Owing to the severity of the disease, pediatric patients with LGG experience a substantial QALY shortfall compared with the general population, and therefore meet the criteria for decision modifiers for severity of disease set out by NICE.” (opens the source at this quote in a new tab)

Scenario and sensitivity analyses in the England and Wales model

“Sensitivity and scenario analyses indicate that the ICER is robust to plausible changes, apart from assumptions around the duration of treatment, treatment effect, and utility values. The ICER is also sensitive to the choice of parametric extrapolation.” (opens the source at this quote in a new tab)
“For completeness, a scenario analysis is conducted using PFS evaluated by the independent assessor (via central lab assessment) leading to an improvement in the incremental cost-effectiveness ratio (ICER) (deterministic ICER: £25 776 vs £14 483) due to earlier progression leading to earlier treatment discontinuation.” (opens the source at this quote in a new tab)

Benefits of oral therapy not captured in the England and Wales model

“This economic analysis has attempted to capture all the potential benefits that are quantifiable; however, there are several potential benefits of treatment with D+T that are not captured within this evaluation including the benefit on NHS capacity through the reduction in patients requiring IV chemotherapy and positive impact on patient and their families/carer quality of life because they may experience increased anxiety and stress having to attend hospital appointments, take time off work, and financial loss.” (opens the source at this quote in a new tab)

Progression-free survival extrapolation in the England and Wales model

“Because parametric distributions did not fit the data well, a piecewise approach is used in the base case, whereby PFS is derived in 3 phases.” (opens the source at this quote in a new tab)
“Phase 1 uses the KM curve for D+T and C+V from TADPOLE up to the next-to-last observed event.” (opens the source at this quote in a new tab)
“This is followed by phase 2, in which the same rate of progression for both D+T and C+V (taken from the log-normal parametric extrapolation from an independent model fitted to C+V only [ie, assumption of no additional benefit for D+T after end of the trial period]) is applied up to the age of 25 years.” (opens the source at this quote in a new tab)
“Finally, phase 3 assumes no further progression once a patient reaches 25 years of age, to account for the diminishing rate of progression over time, and the low likelihood to experience progression as adults based on clinical feedback, and literature that show that adult survivors of pediatric LGGs have low rates of mortality after patients transition into adulthood.” (opens the source at this quote in a new tab)

Post-progression survival by timing of first progression

“Published studies demonstrate that early progressors have poorer outcomes compared with late progressors, suggesting that the timing of progression is important in determining the future outcomes of patients.” (opens the source at this quote in a new tab)

Cost categories, monitoring, and malignant transformation costs in the England and Wales model

“A health service perspective is adopted, and costs are summarized in Table 1. Costs considered include treatment costs (drug acquisition and administration), costs associated with the management of glioma/monitoring of treatments, subsequent treatment costs, palliative care cost, and the costs associated with the management of AEs.” (opens the source at this quote in a new tab)
“The monitoring for patients on treatment was derived from the CCLG guideline and presented in Appendix Table 2 with unit costs taken from the NHS reference cost.” (opens the source at this quote in a new tab)
“The cost associated with the management of patients transforming to malignant glioma is taken from the Scottish Medicines Consortium assessment of adjuvant temozolomide plus radiotherapy and carmustine implants.” (opens the source at this quote in a new tab)

External validation and the evidence constraints acknowledged by the model authors

“Another strength of this study is that internal and external validation were conducted getting clinical inputs and validation against external published data. Predictions were compared with external data for overall survival (Appendix Fig. 3) and shown to broadly align with published data in BRAF V600E mutation-positive pediatric patients with LGG.” (opens the source at this quote in a new tab)
“First, overall survival data in the TADPOLE study are immature, reflecting the long prognosis of patients with LGG; therefore, external evidence in molecularly unselected patient was used as a proxy.” (opens the source at this quote in a new tab)
“Consistent with the majority of economic evaluations, extrapolation beyond the trial period is challenging. Although a piecewise approach is used in the base case because of poor model fit, additional analyses are presented using parametric functions for the entire model duration and alternative forms.” (opens the source at this quote in a new tab)
“Data from molecularly unselected patients are also used when appropriate because of the rarity of the mutation.” (opens the source at this quote in a new tab)

Modeled cohort characteristics used to cost chemotherapy

“The TADPOLE study recruited pediatric patients with LGG aged between 1 and 17 years old (median age: 9.5 years). Most patients were female (60%).” (opens the source at this quote in a new tab)
“The mean weight and body surface area was 43.27 kg (26.291) and 1.26 m2 (0.510), respectively, in the TADPOLE study and only used to costs chemotherapies.” (opens the source at this quote in a new tab)

Line of therapy to which the cost-effectiveness result applies

“Therefore, the D+T combination may also address the unmet need in treating patients with relapsed/refractory pediatric LGG who currently respond poorly to chemotherapy.” (opens the source at this quote in a new tab)
“Further research is required to evaluate the cost-effectiveness for patients receiving D+T after progression on first systemic treatment.” (opens the source at this quote in a new tab)

Germany: evidence the G-BA orphan drug benefit assessment did not take into account

“Da der JCA-Report zu Tovorafenib (JCA-MP-2024-06) zu Beginn des deutschen Nutzenbewertungsverfahrens noch nicht veröffentlicht war, konnte dieser für die vorliegende Nutzenbewertung nicht berücksichtigt werden” (opens the source at this quote in a new tab)
“Aufgrund der in Kapitel 2.6 genannten Limitationen wurde der indirekte Vergleich für die vorliegende Nutzenbewertung nicht herangezogen.” (opens the source at this quote in a new tab)
“Ergebnisse zu Morbiditätsendpunkten wurden aufgrund unklarer Patientenrelevanz (Tumoransprechen, Progressionsfreies Überleben), Unsicherheiten bei der Operationalisierung (Sehschärfe) und geringer Rücklaufquoten (PROMIS-Fragebögen und PedsQL Cancer) nicht berücksichtigt.” (opens the source at this quote in a new tab)
“Bis zum 3-Jahres-Datenschnitt der Studie FIREFLY-1 waren insgesamt 9 Patientinnen und Patienten (6,57 %) in den Studienarmen 1 und 2 verstorben.” (opens the source at this quote in a new tab)

Earlier version of the Canadian microsimulation of first-line dabrafenib plus trametinib

“We constructed a microsimulation model, simulating a cohort of 10,000 patients with BRAFV600E PLGG. We populated the model using progression-free and overall survival estimates derived from the NCT02684058 trial, a hospital-based PLGG registry and treatment- and PLGG-related adverse events from published literature.” (opens the source at this quote in a new tab)
“Modeled life years with Dab-Tram and chemotherapy were 34.91 and 32.68 years, respectively. Dab-Tram was associated with a 1.77 QALY increase at an incremental cost of $2,701,409 compared to standard chemotherapy. The resulting ICER was $1,526,265 per QALY gained. At a willingness-to-pay (WTP) threshold of $150,000 per QALY, a price reduction of approximately 80% is required to render it cost-effective.” (opens the source at this quote in a new tab)

CDA-AMC review: drug acquisition cost comparison and absence of a cost-effectiveness analysis for dabrafenib plus trametinib in pLGG

“For adult patients, based on public list prices, dabrafenib plus trametinib is expected to have a cost of $18,018 per patient per standardized 28-day cycle (Table 1), while vinblastine monotherapy and carboplatin plus vincristine are expected to have costs of $764 and up to $1,410 per patient per standardized 28-day cycle, respectively.” (opens the source at this quote in a new tab)
“For pediatric patients, no public prices were identified for dabrafenib 10 mg tablets for suspension or for trametinib 4.7 mg per bottle oral solution, both indicated for patients aged at least 1 year and weighing at least 8 kg.” (opens the source at this quote in a new tab)
“As such, the reimbursement of dabrafenib plus trametinib as first-line or later therapy for the treatment of LGGs in adult and pediatric patients with residual disease and with known BRAF V600 mutations is expected to increase overall drug acquisition costs.” (opens the source at this quote in a new tab)
“Given that dabrafenib plus trametinib is associated with increased drug acquisition costs and incremental benefit in terms of ORR and PFS compared to carboplatin and vincristine, a cost-effectiveness analysis would be required to determine the cost-effectiveness of dabrafenib plus trametinib relative to comparators.” (opens the source at this quote in a new tab)
“As this was not available, the cost-effectiveness of dabrafenib plus trametinib relative to carboplatin plus vincristine, vinblastine monotherapy, or dabrafenib monotherapy for the treatment of LGGs could not be determined.” (opens the source at this quote in a new tab)

CDA-AMC review: trametinib patent expiry and dabrafenib monotherapy cost comparison

“The patent for trametinib is expected to expire in mid-2025.” (opens the source at this quote in a new tab)
“The earliest-expiring patent for dabrafenib expires in 2029.” (opens the source at this quote in a new tab)
“The incremental cost of dabrafenib plus trametinib compared to dabrafenib alone would be $9,580 per adult patient per 28 days, or $4,844 to $9,580 per patient per 28 days, depending on weight, for pediatric patients weighing at least 26 kg.” (opens the source at this quote in a new tab)

Budget impact model

Approach and framework

No evidence found.

Perspective and time frame

No evidence found.

Epidemiology and eligible population inputs

No evidence found.

Cost assumptions

No evidence found.

Model outcomes

No evidence found.

Results

Base case

No evidence found.

Scenario analyses

No evidence found.

Budget impact model discussion

No evidence found.